drugset / Trial / NCT00574249

Adalimumab in Combination With Topical Treatment (Calcipotriol/Betamethasone) in Subjects With Moderate to Severe Psoriasis and Insufficient Response to Classic Systemic Treatment

NCT00574249

Phase 3 Completed 730 enrolled Abbott
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The objective of this study is to assess the efficacy and safety of adalimumab in combination with topical psoriasis treatment, calcipotriol/betamethasone, vs. adalimumab in combination with matching vehicle in subjects with moderate to severe chronic plaque psoriasis.

Timeline

Start
2007-11
Primary completion
2008-10
Completion

Drugs

EvaluationDrugModalityDoseRoute
Comparator Adalimumab Monoclonal antibody 40 mg Subcutaneous
Comparator Betamethasone Other / unclassified Topical

Indications